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Abstract
Aims To date, evidence to support the construct validity
of the EQ-5D-5L has primarily focused on cross-sectional
data. The aims of this study were to examine the respon-
siveness of EQ-5D-5L in patients with stroke and to
compare it with responsiveness of EQ-5D-3L and visual
analogue scale (EQ VAS).
Methods We performed an observational longitudinal
cohort study of patients with stroke. At 1 week and 4 months
post-stroke, patients were assessed with modified Rankin
Scale (mRS) and Barthel Index (BI) and were administered
the EQ-5D-5L and EQ-5D-3L, including the EQ VAS. The
EQ-5D-5L index scores were derived using the crosswalk
methodology developed by the EuroQol Group. We classi-
fied patients according to two external criteria, based onmRS
or BI, into 3 categories: ‘improvement,’ ‘stable’ or ‘deteri-
oration’. We assessed the responsiveness of each measure in
each patient subgroup using: effect size (ES), standardized
response mean (SRM), F-statistic, relative efficiency and
area under the receiver operating characteristic curve.
Results A total of 112 patients (52 % females; mean age
70.6 years; 93 % ischemic stroke) completed all the instru-
ments at both occasions. In subjectswith clinical improvement,
EQ-5D-5Lwas consistently responsive, showing moderate ES
(0.51–0.71) and moderate to large SRM (0.69–0.86). In gen-
eral, EQ-5D-3L index appeared to be more responsive (ES
0.63–0.82; SRM 0.77–1.06) and EQ VAS less responsive (ES
0.51–0.65; SRM 0.59–0.69) than EQ-5D-5L index.
Conclusions The EQ-5D-5L index, based on the cross-
walk value set, seems to be appropriately responsive in
patients with stroke, 4 months after disease onset. As far as
EQ-5D-5L index is scored according to crosswalk
approach, the EQ-5D-3L index appears to be more
responsive in stroke population.
Keywords EQ-5D-5L  EQ-5D-3L  Health-related
quality of life  Patient-reported outcomes  Psychometrics 
Stroke
Introduction
The EQ-5D is a standardized preference-based measure of
health that provides a simple, generic measure for clinical
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and economic assessment [1, 2]. Its classical, three-level
version (now called EQ-5D-3L) is successfully used as a
secondary outcome in contemporary stroke trials [3]. A
5-level version of the EQ-5D (EQ-5D-5L) was developed
with the goal of improving the sensitivity and other psy-
chometric properties of the original EQ-5D-3L [4, 5].
Janssen and colleagues, in a cross-sectional multi-
country study, reported evidence of the feasibility and
validity of the EQ-5D-5L in a variety of conditions,
showing a low level of missing values, establishing known-
groups validity and showing improved discriminatory
power and improved convergent validity in comparison
with EQ-5D-3L [6]. In the context of two studied popula-
tions with stroke (from UK and from Poland), a 15 %
relative reduction in the ceiling was shown, as well as a
valid redistribution and the highest number of different
health states defined by the questionnaire, in comparison
with other patients groups. Additional studies have been
conducted in Germany, Italy, China, South Korea and
Singapore that also support the validity of the EQ-5D-5L
[7–11]. However, there is a scarcity of studies that have
examined the longitudinal construct validity (i.e., respon-
siveness to change) of the EQ-5D-5L.
Responsiveness is the ability of an outcome instrument
to detect clinically important changes within individuals
with a specific condition [12]. It is evaluated in longitu-
dinal studies of patients, in whom a change is expected to
occur. In general, disease-specific instruments are more
responsive than generic health status measures, as they are
more focused on problems of particular importance to
target patients. Although we have some knowledge about
cross-sectional validity of EQ-5D-5L in stroke patients [6],
we know very little about its responsiveness in stroke
population.
Our objective was to evaluate the responsiveness of the
EQ-5D-5L in a longitudinal study of patients with stroke.
The secondary objective was to compare responsiveness of
EQ-5D-5L index and other generic measures of health-
related quality of life (HRQoL), often used in patients with
stroke—EQ-5D-3L and EQ VAS.
Methods
Study design
A single-center observational longitudinal cohort study was
conducted between July 2009 and May 2010. Three neu-
rologists with experience in the use of clinical measures
assessed patients with primary or recurrent stroke, at two
occasions. Adult patients with primary intracerebral hem-
orrhage or cerebral infarction (I61 or I63 according to ICD-
10 classification) were included. A diagnosis had to be
supported by clinical examination and computed tomog-
raphy (CT) or magnetic resonance imaging (MRI). Indi-
viduals had to be Polish language native speakers. Patients
in coma were excluded. In case of aphasia or dementia, the
survey was administered to family members serving as a
proxy.
The initial survey took place during index hospitaliza-
tion, before discharge. Stroke severity was assessed with
the National Institute of Health Stroke Scale (NIHSS) and
the modified Rankin Scale (mRS), physical performance
with the Barthel Index (BI), and HRQoL with the EQ-5D
generic questionnaire (both five- and three-level versions)
and the EQ-5D visual analogue scale (EQ VAS). Stroke
type was classified according to Oxford Community Stroke
Project (OCSP) classification into: partial anterior circula-
tion stroke (PACS), posterior circulation stroke (POCS),
lacunar stroke (LACS) or total anterior circulation stroke
(TACS). The second survey was conducted after an initial
post-stroke recovery phase about 4 months later, in out-
patient clinics, neurological rehabilitation department or
patients own home. Assessment were completed for the
mRS, BI, EQ-5D-5L, EQ-5D-3L and EQ VAS using paper
and pencil versions of the quality of life questionnaires.
The study conformed to the Helsinki declaration. The
study protocol was approved by the local Ethics Commit-
tee, and all participants gave informed consent before
inclusion.
Measures
The mRS and the BI are widely used stroke outcome
measures in clinical trials and everyday practice [3]. The
mRS is a standardized scale, with good intra-observer
agreement, that evaluates the degree of disability or
dependence in the daily activities of people who have
suffered a stroke or neurological disability, providing a
score that ranges from 0 (perfect health without symptoms)
to 6 (death) [13]. BI is a valid measure of activities of daily
living with a substantial body of literature describing its
clinimetrics [14]. It has good reliability and reasonable
responsiveness. Although sensitivity to change is limited at
the extremes of disability (floor and ceiling effects), BI
seems to be more sensitive than other common stroke
scales [15]. We used the 10-item scale, scoring 0–100 with
5-point increments [16].
EQ-5D is a brief measure of health that has been used
extensively in stroke [17]. It is available for self-comple-
tion or by proxy using paper and pencil or electronic ver-
sions (PDA, tablet and WWW). Both the EQ-5D-3L and
EQ-5D-5L consist of 2 parts: a descriptive health classifier
system and a visual analogue scale (EQ VAS). The EQ-5D-
5L descriptive system comprises the same five dimensions
as the EQ-5D-3L (mobility, self-care, usual activities, pain/
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discomfort and anxiety/depression), but has five levels of
severity (no problems, slight problems, moderate problems,
severe problems and extreme problems) rather than three
levels (no problems, some problems and extreme prob-
lems) in EQ-5D-3L. The responses for the five dimensions
can be combined in a 5-digit number describing the
respondent’s health state (from ‘11111’ meaning no prob-
lems at all to ‘55555’ meaning extreme problems in all five
dimensions) [5]. A total of 243 and 3,125 possible health
states are defined in this way in EQ-5D-3L and EQ-5D-5L,
respectively. EQ-5D health states may be converted into a
single summary index by applying a formula that attaches
values (also called weights) to each of the levels in each
dimension that can facilitate cost–utility analyses. To
obtain EQ-5D-3L index values, we used the Polish EQ-5D-
3L value set derived using the time trade-off valuation
technique [18] and to obtain EQ-5D-5L index scores, we
used Polish interim EQ-5D-5L value set estimated using
the crosswalk methodology developed by the EuroQol
Group [19, 20]. The EQ VAS derives information about the
respondents’ subjective health perception, scored on a
20-cm visual analogue scale with endpoints labeled ‘the
best health you can imagine’ and ‘the worst health you can
imagine.’
Responsiveness
Responsiveness has been defined as the ability to detect
changes that are meaningful or clinically important [21].
To assess responsiveness, some criterion is needed to
identify whether patients have changed (either improved or
worsened) over time [22]. It is strongly recommended to
use multiple independent anchors [23]. We used two
external criteria (EC) based on clinical outcomes, namely
mRS and BI change scores. The first criterion was based on
movement between categories on the mRS at baseline and
follow-up: improvement of at least one level (improve-
ment), no movement (stable) and decline at least one level
(deterioration). We made no differentiation between
‘some’ change and ‘large’ change, as there were only a
small subset of patients who changed two or more levels.
There are several different ways with different cut points to
categorize BI outcomes [24]. Due to lack of consensus on
the approach, we used the minimal clinically important
difference (MCID) of the BI in stroke patients estimated by
Hsiech et al. [25] of 1.85 points on a 20-point scale (or 9.25
on a 100-point scale).The BI criterion was defined as fol-
lows: improvement of at least 9.25 points (improvement),
deterioration of at least 9.25 points (deterioration), deteri-
oration of \9.25 points, no change or improvement of
\9.25 points (stable).
Analysis
First, correlations between the change scores of the mea-
sures were examined using Spearman’s rank correlation
coefficient (rs). The extent of correlation was interpreted as
absent (\0.20), poor (0.20–0.34), moderate (0.35 - 0.50) or
strong ([0.50) [26].
Responsiveness was evaluated using the following sta-
tistical approaches: (1) effect size, (2) standardized
response mean, (3) F-statistic, (4) relative efficiency and
(5) area under the receiver operating characteristic curve.
We calculated effect size (ES) as the ratio of the mean
change to the standard deviation (SD) of initial measure-
ment, standardized response mean (SRM) as the ratio of the
mean change to the SD of that change and the F-statistic as
a squared t-statistic (squared ratio of the mean change to
the standard error of that change). The ES construct ignores
the variation in the change, and the SRM construct makes it
less sensitive to sample sizes than ES [27]. Both ES and
SRM were interpreted as large ([0.8), moderate (0.5–0.8)
or small (\0.5) [28, 29]. In analyzing test statistics, a
Table 1 Demographic characteristics of studied population with
stroke
First survey Follow-up
N 112
Age, years
Mean (SD) 70.6 (11.0)
Range 39–88
Sex, F, n (%) 58 (51.8)
ICD-10, n (%)
I61 (intracerebral hemorrhage) 8 (7.1)
I63 (cerebral infarction) 104 (92.9)
mRS, n (%)
0 2 (1.8) 5 (4.5)
1 23 (20.5) 32 (28.6)
2 42 (37.5) 42 (37.5)
3 21 (18.8) 16 (14.3)
4 14 (12.5) 8 (7.1)
5 10 (8.9) 9 (8.0)
NIHSS
Mean (SD) 4.1 (4.8)
Assessment site, n (%)
Hospital ward 105 (93.8) 4 (3.6)
Outpatient clinic 5 (4.5) 85 (75.9)
Rehabilitation ward 2 (1.8) 3 (2.7)
Home 0 (0) 20 (17.9)
Respondent, n (%)
Patient 91 (81.3) 102 (91.1)
Proxy 21 (18.7) 10 (8.9)
mRS modified Rankin scale, NIHSS National institute of health stroke
scale
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measure that generates the largest statistic is judged to be
the most responsive. To compare the responsiveness of
measures, relative efficiency (RE) was calculated by taking
a ratio of F-statistics, where the measure with the smallest
F-statistic served as the reference, which results in all
coefficients being greater than 1.
Receiver operating characteristic (ROC) curves were
used to assess the sensitivity and specificity of different
change scores [30]. We calculated the size of the area
under the curve (AUROC), which corresponds to the
probability of correctly identifying patients with a specified
outcome according to the EC. AUROC may range from 0.5
(no discriminatory accuracy) to 1.0 (perfect accuracy) in
distinguishing patients identified by this criterion [27]. We
performed three groups of comparisons: improved versus
stable, deteriorated versus stable and improved versus
deteriorated patients.
The statistical software used was the StatsDirect 2.7.8
(StatsDirect Ltd, England). The area under the ROC was
estimated by a nonparametric method analogous to the
Wilcoxon/Mann–Whitney test [31]. Accompanying confi-
dence intervals were constructed using DeLong’s variance
estimate [32]. All tests were two-sided. The results were
considered significant at P\ 0.05.
Results
One hundred and fourteen patients were followed up for
about 4 months (median 107.5 days; interquartile range
(IQR) 101–123) after the initial stroke hospitalization and
after a median of 98.5 days (IQR 93–111) since the first
survey. Two patients were excluded from the final analysis,
because of missing data: one on initial and follow-up mRS
and one on follow-up EQ-5D-5L and EQ-5D-3L. Charac-
teristics of the included 112 subjects are presented in
Table 1. The majority of patients had secondary (32 %) or
higher (22 %) education, were retired (71 %) or pensioners
(15 %), lived with their relatives (79 %) or lived indepen-
dently (20 %). Comorbidities were common in the studied
population: hypertension in 72 % of patients, coronary
artery disease in 31 %, diabetes in 25 %, atrial fibrillation in
21 % and cardiac insufficiency in 16 %. Thirty-one percent
of subjects were current smokers. The most common stroke
symptoms included: upper extremity (79 %) or lower
extremity paresis (64 %), dysphasia (33 %), hemianopsia
(16 %), dysarthria (31 %) or brain stem or cerebral sings
(15 %). In 54 % and 40 % of patients, stroke involved right
and left side of the body, respectively, with no obvious side
affected in 4 %.According toOCSP stroke classification, the
sample was composed of: 46 % PACS, 26 % POCS, 20 %
LACS and 7 %TACS. For 20 % of patients, it was recurrent
stroke. Median hospital stay was 10 days (IQR 8–14 days),
and median intensive care unit stay was 1 day (IQR
0–2 days). Patients were discharged to their own house
(77 %), rehabilitation ward (17 %) or transferred to another
hospital (5 %).
Between baseline and follow-up, all clinical and
HRQoL measures showed improvement based on mean
and median scores (paired t tests all \0.01; Table 2).
Significant differences in the distribution of responses to
self-care and usual activities EQ-5D-5L dimensions were
observed (Chi-squared tests \0.001 and 0.001, respec-
tively) (Table 3).
Correlation between change scores of each measure
revealed that changes in EQ-5D-5L were strongly correlated
Table 2 Descriptive statistics
for HRQoL and clinical
outcome measures
EQ VAS EQ-5D visual analogue
scale, mRS modified Rankin
scale
Mean (SD) Median (Q1–Q3) Range %
Floor
%
Ceiling
%
Negative
Baseline
EQ-5D-5L
index
0.577 (0.343) 0.724 (0.478–0.791) -0.523 to
1.0
1.8 5.4 8.0
EQ-5D-3L
index
0.584 (0.353) 0.716 (0.369–0.798) -0.523 to
1.0
2.7 6.3 7.1
EQ VAS 54.3 (24.8) 50 (40–70) 0–100 1.8 3.6 –
Barthel index 78.9 (30.4) 95 (70–100) 0–100 2.7 49.1 –
mRS 2.5 (1.3) 2 (2–3) 5–0 8.9 1.8 –
Follow-up
EQ-5D-5L
index
0.691 (0.267) 0.741 (0.619–0.861) -0.231 to
1.0
0.0 7.1 4.5
EQ-5D-3L
index
0.694 (0.281) 0.768 (0.716–0.868) -0.523 to
1.0
0.9 9.8 1.8
EQ VAS 60.7 (22.4) 60 (45.5–80) 0–100 0.9 1.8 –
Barthel Index 84.6 (26.3) 100 (80–100) 0–100 3.6 55.4 –
mRS 2.2 (1.3) 2 (1–3) 5–0 8.0 4.5 –
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withEQ-5D-3L,moderatelywithEQVASandBI and poorly
with the mRS (Table 4). EQ-5D-3L tended to have stronger
levels of correlation with stroke clinical outcome measures
than EQ-5D-5L. The weakest observed correlation was
between EQ VAS and mRS or BI change scores. Surpris-
ingly, the correlation between mRS and BI change scores
was only moderate.
According to our predefined mRS external anchor,
slightly more patients were defined as improved (38.4 %)
or deteriorated (17.0 %) compared with findings based on
the BI as an external anchor (33.0 % and 13.4 %, respec-
tively). Table 5 shows change scores for each measure
stratified by subgroup when defined by each of the external
criteria (mRS and BI). In general, mean EQ-5D-3L index
changes were greater than mean EQ-5D-5L index changes,
and the latter were greater than EQ VAS changes.
In the analysis based on external criteria, both ES and
SRM are higher when patients were classified as
‘improved,’ rather than ‘deteriorated.’ In subjects who
improved, indices showed at least moderate responsive-
ness, with responsiveness statistics associated with the EQ-
5D-3L index being consistently more responsive than EQ-
5D-5L index. In patients who improved based on the BI,
both the EQ-5D-3L index and the EQ-5D-5L captured
large magnitudes of effect according to the SRM. A similar
pattern was observed using mRS as the basis for catego-
rizing patients into outcome groups (Table 6).
Responsiveness analysis based on ROC curves similarly
found that the BI worked better than mRS as an external
criterion, giving higher AUROC, which indicates better
accuracy. Systematically, the most responsive measure was
the EQ-5D-3L index. When the external criterion was
based on BI, the second most responsive instrument was
the EQ-5D-5L, but when EC was based on mRS, the sec-
ond was EQ VAS (Table 7).
Discussion
In the present study, the EQ-5D-5L showed appropriate
responsiveness in patients about 4 months after stroke, as
confirmed by using several indices—ES, SRM, F-statistic,
RE and area under the ROC curve. We noticed moderate
ESs and moderate to large SRMs. Nevertheless, in our
sample of stroke patients, EQ-5D-3L index appeared to be
more responsive than EQ-5D-5L index scored according to
Table 3 Distribution of EQ-5D-5L dimension responses at baseline
and at follow-up (N = 112)
Dimension Baseline
n (%)
Follow-up
n (%)
P value*
Mobility
No problems 17 (15.2) 34 (30.4) 0.057
Slight problems 28 (25.0) 24 (21.4)
Moderate problems 31 (27.7) 29 (25.9)
Severe problems 18 (16.1) 16 (14.3)
Unable to walk about 18 (16.1) 9 (8.0)
Self-care
No problems 28 (25.0) 55 (49.1) \0.001
Slight problems 27 (24.1) 19 (17.0)
Moderate problems 22 (19.6) 18 (16.1)
Severe problems 10 (8.9) 12 (10.7)
Unable to wash or dress 25 (22.3) 8 (7.1)
Usual activities
No problems 16 (14.3) 30 (26.8) 0.001
Slight problems 29 (25.9) 27 (24.1)
Moderate problems 28 (25.0) 26 (23.2)
Severe problems 10 (8.9) 20 (17.9)
Unable to do usual
activities
29 (25.9) 9 (8.0)
Pain/discomfort
No pain or discomfort 24 (21.4) 29 (25.9) NS
Slight pain or discomfort 26 (23.2) 24 (21.4)
Moderate pain or
discomfort
41 (36.6) 40 (35.7)
Severe pain or discomfort 19 (17.0) 15 (13.4)
Extreme pain or
discomfort
2 (1.8) 4 (3.6)
Anxiety/depression
Not anxious or depressed 20 (17.9) 26 (23.2) NS
Slightly anxious or
depressed
36 (32.1) 44 (39.3)
Moderately anxious or
depressed
33 (29.5) 31 (27.7)
Severely anxious or
depressed
20 (17.9) 9 (8.0)
Extremely anxious or
depressed
3 (2.7) 2 (1.8)
* Chi-square test, NS non significant
Table 4 Correlations between change scores of studied measures
(Spearman’s rank correlation coefficient)
EQ-5D-5L
index
EQ-5D-3L
index
EQ
VAS
Barthel
Index
mRS
EQ-5D-5L
index
1.00
EQ-5D-3L
index
0.74 1.00
EQ VAS 0.48 0.41 1.00
Barthel
index
0.43 0.56 0.27 1.00
mRS -0.31 -0.41 -0.32 -0.42 1.00
EQ VAS EQ-5D visual analogue scale, mRS modified Rankin scale
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crosswalk approach. Contrary, EQ VAS showed to func-
tion worse in the studied context.
The finding that in stroke patients EQ-5D-5L appears to
be less responsive than EQ-5D-3L may be seen unex-
pected, as five-level version was developed with the goal of
improving psychometric properties of the three-level EQ-
5D. It should be viewed in terms of limitations of the value
set we used. An important limitation of the current study
was reliance on an interim EQ-5D-5L value set derived
from a crosswalk algorithm [20]. Index scores based on
mapping functions are less reliable than scores from value
sets based on preferences directly elicited from represen-
tative general population samples. In other study, we found
that the Polish interim EQ-5D-5L value set generated
values to some extent more narrow, than those generated
by the EQ-5D-3L time trade-off value set. There were
relatively less health states valued ‘worse than death’ or as
a good health and, at the same time, relatively more health
Table 5 Descriptive statistics (mean, SD) for HRQoL and clinical outcome measures in patients classified as improved, stable or deteriorated,
according to external criterion
Measure Time
point
mRS-based external criterion Barthel index-based external criterion
Improved
N = 43
Stable
N = 50
Deteriorated
N = 19
Improved
N = 37
Stable
N = 60
Deteriorated
N = 15
EQ-5D-5L
index
Baseline 0.529 (0.388) 0.590 (0.333) 0.652 (0.246) 0.341 (0.376) 0.716 (0.242) 0.603 (0.304)
Follow-up 0.729 (0.217) 0.696 (0.292) 0.590 (0.292) 0.607 (0.232) 0.795 (0.177) 0.482 (0.429)
Change 0.200 (0.290) 0.106 (0.214) -0.061 (0.247) 0.267 (0.311) 0.078 (0.165) -0.121 (0.256)
EQ-5D-3L
index
Baseline 0.531 (0.382) 0.595 (0.357) 0.674 (0.253) 0.323 (0.377) 0.731 (0.248) 0.637 (0.293)
Follow-up 0.769 (0.174) 0.691 (0.286) 0.530 (0.150) 0.634 (0.228) 0.796 (0.198) 0.434 (0.445)
Change 0.239 (0.309) 0.096 (0.189) -0.144 (0.381) 0.310 (0.294) 0.065 (0.202) -0.203 (0.352)
EQ VAS Baseline 51.3 (25.1) 56.9 (25.6) 53.9 (22.7) 38.1 (20.3) 64.5 (22.0) 53.0 (25.4)
Follow-up 64.1 (19.8) 64.2 (22.0) 43.6 (22.1) 51.3 (17.9) 69.2 (19.3) 49.6 (29.9)
Change 12.8 (21.5) 7.3 (20.5) -10.3 (17.4) 13.2 (19.1) 4.72 (24.1) -3.4 (11.2)
EQ VAS EQ-5D visual analogue scale, mRS modified Rankin scale
Table 6 Responsiveness
statistics for HRQoL and
clinical measures by external
criterion
EQ VAS EQ-5D visual analogue
scale, mRS modified Rankin
scale
Responsiveness
statistic
Measure mRS-based external criterion Barthel index-based external
criterion
Improved
N = 43
Deteriorated
N = 19
Improved
N = 37
Deteriorated
N = 15
Effect size EQ-5D-5L
index
0.51 -0.25 0.71 -0.40
EQ-5D-3L
index
0.63 -0.57 0.82 -0.69
EQ VAS 0.51 -0.45 0.65 -0.13
Standardized
response mean
EQ-5D-5L
index
0.69 -0.25 0.86 -0.47
EQ-5D-3L
index
0.77 -0.38 1.06 -0.58
EQ VAS 0.59 -0.59 0.69 -0.30
F-statistic EQ-5D-5L
index
20.32 1.17 27.15 3.36
EQ-5D-3L
index
25.68 2.70 41.30 4.98
EQ VAS 15.25 6.72 17.65 1.38
Relative efficiency EQ-5D-5L
index
1.33 1.00 1.54 2.43
EQ-5D-3L
index
1.68 2.31 2.34 3.60
EQ VAS 1.00 5.75 1.00 1.00
1560 Qual Life Res (2015) 24:1555–1563
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states valued moderately [20]. Moving from ‘bad health’ to
‘good health’ resulted in a smaller change in the EQ-5D-5L
index value based on crosswalk methodology than in the
directly measured EQ-5D-3L index value. Although many
approaches were explored by the EuroQol research team
that published the crosswalk algorithm [19], it should be
considered second best to direct utility measurement. At
the moment, directly measured value sets for EQ-5D-5L
are under development [33, 34]. EQ-5D-5L responsiveness
properties should be revisited when these sets become
available.
There is no ‘gold standard,’ i.e., which measure is
superior in establishing whether a relevant or significant
change in HRQoL of stroke patients has occurred. The use
of multiple clinical anchor-based criteria of change is
advised. In the present study, we identified patients with
improvement or worsening based on a general disability
measure—mRS and a physical performance based mea-
sure—BI. It can be argued that the use of a different
HRQoL measure as an anchor may give more reliable
results, but both mRS and BI are recognized as the most
often used standard of stroke outcome measurement [3]
and were successfully used in studies of responsiveness of
preference-based generic HRQoL measures in stroke [35].
Responsiveness of studied instruments was higher when
external criterion was based on BI, rather than mRS. It can
be that the studied indices are closely correlated with BI or
that our mRS measurement had limited reliability. The
mRS is the preferred measure of disability in stroke trials,
but its value is restricted by potentially significant inter-
observer variability [36, 37]. Several attempts were made
to reduce the bias between mRS raters, such as introduction
of a structured interview, video-based training and certifi-
cation, but effects have not been consistent [38]. Another
explanation could be that we allowed the use of proxies, in
case of aphasia or dementia. In our study, surveys
performed in this way constituted less than 20 % during the
first survey and less than 10 % at follow-up. Some authors
reported that patient’s assessment of HRQoL has a stronger
association with mRS, while proxy responses have a
stronger association with BI [39].
Contrary to other authors, we made no differentiation
between some and large improvement, as there were only
some patients with a shift of two or more levels in mRS
[35]. We also did not exclude patients who deteriorated.
Final numbers of patients with deterioration, according to
mRS and BI external anchors, were low (19 and 15,
respectively), posing a question about validity and gener-
alizability of results obtained in these groups.
To our best knowledge, this is the first study of EQ-5D-
5L responsiveness in patients with stroke. The three-level
version of EQ-5D was investigated in this context, twice.
Hunger and colleagues showed reasonable validity, reli-
ability and more limited responsiveness of a sample of
German patients with a history of stroke, mild to moderate
limitations of functional status, undergoing neurological
rehabilitation [17]. Observed ESs were lower than esti-
mated by Pickard et al. [35] and in our study. A possible
explanation is that patients in the German study were
included later after the stroke onset (median 5.7 weeks)
and characterized with better functional status. As noticed
by Pickard et al., the EQ-5D index is highly responsive in
conditions where extreme health problems are encountered
initially and subsequently improve. EQ-5D, with five
dimensions and three levels, was as efficient in capturing
changes as SF-6D, with six dimensions and four to six
levels and Health Utility Index-3 (HUI3), with eight
dimensions and five or six levels [35].
Our study is one of the first to examine the respon-
siveness of the EQ-5D-5L. Up till now, this topic was
investigated only in women with breast cancer [11] and
patients undergoing colonoscopy [40]. Swan and
Table 7 Area under the receiver operating characteristic curve (AUROC) analysis
Compared populations Measure AUROC (95 % CI)
External criterion: mRS External criterion: BI
Improved versus stable EQ-5D-5L index 0.57 (0.45–0.69) 0.71 (0.59–0.83)
EQ-5D-3L index 0.63 (0.52–0.75) 0.79 (0.69–0.89)
EQ VAS 0.58 (0.46–0.69) 0.62 (0.50–0.73)
Deteriorated versus stable EQ-5D-5L index 0.70 (0.44–0.95) 0.70 (0.41–1.00)
EQ-5D-3L index 0.74 (0.45–1.00) 0.75 (0.43–1.00)
EQ VAS 0.74 (0.45–1.00) 0.63 (0.43–0.82)
Improved versus deteriorated EQ-5D-5L index 0.75 (0.62–0.89) 0.83 (0.72–0.94)
EQ-5D-3L index 0.81 (0.69–0.93) 0.91 (0.84–0.98)
EQ VAS 0.80 (0.69–0.92) 0.75 (0.62–0.88)
AUROC area under the receiver operating characteristic curve, BI Barhel index, mRS modified Rankin scale
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colleagues stated that EQ-5D-5L is unresponsive in
colonoscopy patients, with the SRM and the ES moderately
positive and a significant baseline to post-procedure change
in the direction unexpected by authors. In contrast, Lee and
coauthors, assessing EQ-5D-5L responsiveness in breast
cancer patients, found it reasonably responsive with
ES = 0.52 and 0.69, when external criterion was based on
self-assessed performance status or self-rated change in
quality of life, respectively.
Future studies of the EQ-5D-5L in stroke patients should,
also, provide an in-depth look at its validity and reliability,
especially in the context of test–retest reliability.
We conclude that the EQ-5D-5L index, based on the
crosswalk value set, seems to be appropriately responsive
in patients with stroke, 4 months after disease onset. As far
as EQ-5D-5L index is scored according to crosswalk
approach, the EQ-5D-3L index appears to be more
responsive in stroke population.
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